Broker: CGS International
Date of Report: July 29, 2026
Excerpt from CGS International report.
Report Summary
Stock Focus: iX Biopharma Ltd (SIN: iX Biopharma Ltd)
Actionable Idea: The report highlights a technical update on iX Biopharma Ltd, identifying a bullish re-accumulation phase as completed. The stock has shown a strong bullish continuation, confirming the positive momentum.
- Current Price: S\$0.515
- Action: Prefer to add on pullback.
- Entry Levels: S\$0.465, S\$0.440
- Stop Loss: S\$0.340
- Key Support Levels: S\$0.460, S\$0.320
- Target Prices:
- TP1: S\$0.590
- TP2: S\$0.660
- TP3: S\$0.780
- TP4: S\$1.00
- Resistance Levels: S\$0.620, S\$0.800
Implications: The price action has confirmed a bullish re-accumulation, with a strong parabolic rise. The analyst recommends shifting the stop loss to S$0.340 and increasing the long-term target price to S$0.780. Investors are advised to consider entry on a pullback for optimal risk management.
Above is an excerpt from a report by CGS International. Clients of CGS International can access the full research report from the broker’s website.
CGS International research website
